Acadia Pharmaceuticals Target Price

Where could ACAD trade next? Consensus target price: $33.

Get informed when a big investor buys or sells

+ Follow

Share Price

$18.14

Average Target Price

$32.66

80% upside

16 analysts in the last 4 months

High: $49 | Low: $14.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-11-05	RBC CapitalBrian Abrahams	$38	109.5% upside
2026-10-13	UBS	$23	26.8% upside
2026-09-28	William Blair	$33	81.9% upside
2026-09-25	H.C. WainwrightAnanda Ghosh	$33	81.9% upside
2026-09-25	Deutsche BankDavid Hoang	$31	70.9% upside
2026-09-25	BMO Capital	$34	87.4% upside
2026-09-25	NeedhamAmi Fadia	$35	92.9% upside
2026-08-25	Deutsche Bank	$38	109.5% upside
2026-08-25	Morgan Stanley	$28	54.4% upside
2026-08-17	UBS	$49	170.1% upside
2026-08-12	NeedhamAmi Fadia	$41	126% upside
2026-08-10	Morgan Stanley	$27	48.8% upside
2026-08-05	RBC CapitalBrian Abrahams	$37	104% upside
2026-08-05	OppenheimerMatthew Hershenhorn	$25	37.8% upside
2026-07-29	Raymond James	$14.5	20.1% downside
2026-07-21	BMO Capital	$36	98.5% upside
2026-07-07	RBC CapitalBrian Abrahams	$36	98.5% upside
2026-06-29	Deutsche BankDavid Hoang	$37	104% upside
2026-06-29	Canaccord GenuitySumant Kulkarni	$36	98.5% upside
2026-03-02	William Blair	$29	59.9% upside
2026-02-23	Wolfe ResearchRudy Li	$33	81.9% upside
2026-02-23	Mizuho Securities	$35	92.9% upside
2026-02-03	RBC Capital	$31	70.9% upside
2026-01-06	UBSAshwani Verma	$40	120.5% upside
2026-01-05	Needham	$34	87.4% upside
2025-12-16	Piper Sandler	$37	104% upside
2025-12-16	Stifel Nicolaus	$37	104% upside
2025-12-15	H.C. Wainwright	$37	104% upside
2025-12-11	Stifel NicolausPaul Matteis	$25	37.8% upside
2025-12-04	UBSAshwani Verma	$35	92.9% upside
2025-12-02	Mizuho Securities	$29	59.9% upside
2025-09-25	Deutsche Bank	$29	59.9% upside
2025-09-09	UBS	$39	115% upside
2025-08-08	UBSAshwani Verma	$36	98.5% upside
2025-06-26	OppenheimerMatthew Hershenhorn	$22	21.3% upside
2025-05-20	Morgan StanleySean Laaman	$24	32.3% upside
2025-05-19	NeedhamAmi Fadia	$30	65.4% upside
2025-05-19	H.C. WainwrightAndrew Fein	$32	76.4% upside
2025-04-28	UBS	$22	21.3% upside
2025-01-03	GuggenheimYatin Suneja	$20	10.3% upside
2024-08-07	Morgan StanleyJeffrey Hung	$20	10.3% upside
2024-06-26	BMO CapitalKeith Tapper	$31	70.9% upside
2024-05-09	H.C. WainwrightAndrew Fein	$27	48.8% upside
2024-05-09	Robert W. BairdJoel Beatty	$28	54.4% upside
2024-05-09	Mizuho SecuritiesUy Ear	$21	15.8% upside
2024-04-30	UBSAshwani Verma	$27	48.8% upside
2024-03-12	UBSAshwani Verma	$33	81.9% upside
2024-03-12	OppenheimerJay Olson	$19	4.7% upside
2024-03-12	NeedhamAmi Fadia	$32	76.4% upside
2024-03-12	Canaccord GenuitySumant Kulkami	$33	81.9% upside

Acadia Pharmaceuticals (ACAD) FAQ

Acadia Pharmaceuticals (ACAD) currently reports a target price of $33. Use the charts on this page to explore Acadia Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Acadia Pharmaceuticals is $33, about 80.0% upside from the current share price of $18.14. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $33, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acadia Pharmaceuticals, and consider following ACAD for alerts when major investors trade the stock.

Acadia Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $33. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACAD with unrelated industries.